Bibliographic Details
| Title: |
Proprotein convertase subtilisin/kexin type 9 (PCSK9) and clinical outcomes in dialysis patients. |
| Authors: |
Torino, Claudia, Carbone, Federico, Pizzini, Patrizia, Mezzatesta, Sabrina, D'Arrigo, Graziella, Gori, Mercedes, Liberale, Luca, Moriero, Margherita, Michelauz, Cristina, Frè, Federica, Isoppo, Simone, Gavoci, Aurora, La Rosa, Federica, Scuricini, Alessandro, Tirandi, Amedeo, Ramoni, Davide, Mallamaci, Francesca, Tripepi, Giovanni, Montecucco, Fabrizio, Zoccali, Carmine |
| Source: |
European Journal of Clinical Investigation; Sep2024, Vol. 54 Issue 9, p1-9, 9p |
| Subject Terms: |
BLACK South Africans, LOW density lipoprotein receptors, HEMODIALYSIS patients, SUBTILISINS, REGRESSION analysis |
| Abstract: |
Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9), a factor accelerating the degradation of LDL receptors, was associated with a gender‐dependent risk for cardiovascular (CV) events in the general population and with all‐cause and CV mortality in two relatively small studies in black Africans and South Korean haemodialysis patients. The effect modification by gender was untested in these studies. Methods: The study enrolled 1188 dialysis patients from the Prospective Registry of The Working Group of Epidemiology of Dialysis Region Calabria (PROGREDIRE) cohort. PCSK9 was measured by colorimetric enzyme‐linked immunosorbent assay. The primary outcomes were all‐cause and CV mortality. Statistical analysis included Cox regression analysis and effect modification analysis. Results: During a median 2.9‐year follow‐up, out of 494 deaths, 278 were CV‐related. In unadjusted analyses, PCSK9 levels correlated with increased all‐cause (HRfor1ln unit increase: 1.23, 95% CI 1.06–1.43, p =.008) and CV mortality (HRfor1ln unit increase: 1.26, 95% CI 1.03–1.54, p =.03). After multivariate adjustment, these associations were no longer significant (all‐cause mortality, HRfor 1 ln unit increase: 1.16, 95% CI.99–1.36, p =.07; CV mortality, HRfor1ln unit increase: 1.18, 95% CI.95–1.46, p =.14). However, in fully adjusted interaction analyses, a doubling in the risk of this outcome in women was registered (Women, HRfor1ln unit increase: 1.88, 95% CI 1.27–2.78, p =.002; Men, HRfor1ln unit increase: 1.07, 95% CI.83–1.38, p =.61; p for effect modification:.02). Conclusions: PCSK9 levels are unrelated to all‐cause mortality in haemodialysis patients but, like in studies of the general population, independently of other risk factors, entail a doubling in the risk of CV events in women in this population. [ABSTRACT FROM AUTHOR] |
|
Copyright of European Journal of Clinical Investigation is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
